Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Cancer
- Pharmaceuticals
- Disease
- Therapeutic
- Antibody
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1346
IPSCIO Record ID: 30031
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.
IPSCIO Record ID: 260380
For the Evaluation License, Licensor grants a nonexclusive, non-transferable, worldwide right and license, with rights to sublicense, for the Term of this Agreement, under all intellectual property rights owned or controlled by Licensor as of the Effective Date or at any time during the Term, to evaluate the Secondary Assets, and all materials and information relating thereto, including without limitation the Secondary Asset Preliminary Materials, solely for the purposes of determining whether Licensee desires to exercise the Option with respect to any such Secondary Assets.
Product means any antibody product, including, without limitation, fragments thereof, produced by Licensee, its Affiliates or sublicensees from the Assets.
Primary Asset means CHOBC® cell lines producing the biosimilar monoclonal antibody Trastuzumab; unmodified descendants of those cell lines; unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.
Secondary Assets means the Bevacizumab Asset and the Rituximab Asset.
Bevacizumab Asset means CHOBC® cell lines producing biosimilar monoclonal antibodies to Bevacizumab; unmodified descendants of those cell lines; unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.
Rituximab Asset means CHOBC® cell lines producing biosimilar monoclonal antibodies to Rituxhnab; unmodified descendants of those cell lines; unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.
Bevacizumab is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
Trastuzumab is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive.
